Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.01 Analyst target: $104.00 Upside: 10197.03%
NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
See the full interactive analysis & chart →Informational only — not investment advice.